Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Appointed director
Quarterly results
Director departure
Inv. presentation
|
|
China Biologic Products Holdings, Inc. (CBPO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/21/2017 |
8-K
| Form 8-K - Current report: |
| 06/30/2017 |
8-K
| Form 8-K - Current report |
| 05/03/2017 |
8-K
| Form 8-K - Current report |
| 04/28/2017 |
8-K
| Form 8-K - Current report |
| 02/23/2017 |
8-K
| Form 8-K - Current report |
| 01/06/2017 |
8-K
| Form 8-K - Current report |
| 01/04/2017 |
8-K
| Form 8-K - Current report |
| 11/08/2016 |
8-K
| Other Events |
| 11/02/2016 |
8-K
| Form 8-K - Current report |
| 11/02/2016 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 10/31/2016 |
8-K
| Form 8-K - Current report |
| 10/11/2016 |
8-K
| Form 8-K - Current report |
| 09/20/2016 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation Factor IX BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug Administration to begin human clinical trials on its Human Coagulation Factor IX product. Human Coagulation FIX is intended for use in the therapy of prevention and control of bleeding in patients who suffer from inherited FIX deficiency, known as hemophilia B, or acquired clotting FIX deficiency. The World Federation of Hemophilia estimates that approximately 80,000 to 120,000 individuals in China ..." |
|
| 08/16/2016 |
8-K
| Resignation/termination of a director |
| 08/04/2016 |
8-K
| Form 8-K - Current report |
| 06/20/2016 |
8-K
| Form 8-K - Current report |
| 06/13/2016 |
8-K
| Form 8-K - Current report |
| 06/06/2016 |
8-K
| Form 8-K - Current report |
| 05/04/2016 |
8-K
| Form 8-K - Current report |
| 03/08/2016 |
8-K
| Form 8-K - Current report |
| 03/04/2016 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and among the Company, the Selling Stockholders and the Underwriter",
"Amended and Restated Underwriting Agreement, by and among the Company, the Selling Stockholders and the Underwriter",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation",
"China Biologic Products, Inc.",
"China Biologic Products, Inc." |
|
| 02/25/2016 |
8-K
| Quarterly results |
| 01/04/2016 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/03/2015 |
8-K
| Quarterly results |
| 10/20/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"China Biologic Received Operating Permit for New Branch Collection Facility in Shandong Province BEIJING, China – October 20, 2015 – China Biologic Products, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, on October 19, 2015, the Company’ s majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd. , received the operating permit from local authorities to commence plasma collection at the new branch collection facility in Zaozhuang City, Shandong Province. As previously announced, Shandong Taibang received approval to build this new branch collection facility in September 2015. This new branch collection facility will operate under the Company’ s Ningyang plasma collection station and cover the collection territory of ..." |
|
| 09/08/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"China Biologic to Build New Branch Collection Facility in Shandong Province BEIJING, China – September 8, 2015 – China Biologic Products, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd. received approval from the Shandong Provincial Health and Family Planning Commission on September 1, 2015 to build a new branch collection facility in Shandong Province, which will operate under the Company’ s Ningyang plasma collection station. This new plasma collection facility, located in Shanting District of Zaozhuang City, will be a branch of the existing Ningyang plasma collection station, which was established in July 2011. The new collection facility will cover the col..." |
|
| 09/02/2015 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 08/05/2015 |
8-K
| Quarterly results |
| 06/23/2015 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/16/2015 |
8-K
| Regulation FD Disclosure |
| 06/10/2015 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and between the Company, the Selling Stockholders and the representatives to the Underwriters",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation",
"China Biologic Announces Pricing of Public Offering of Common Stock BEIJING, China – June 10, 2015 – China Biologic Products, Inc. , a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 3,000,000 shares of common stock at a public offering price of $105 per share. The Company will be offering 700,000 shares and certain selling stockholders will be offering 2,300,000 shares of common stock. In addition, the underwriters have a 30-day option to purchase up to 105,000 additional shares of common stock from the Company and 345,000 additional shares of common stock from the selling stockholders. The Company intends to use the proceeds from the offering primarily for general corporate purposes. In addition, if appropriate opportunities..." |
|
| 05/06/2015 |
8-K
| Quarterly results |
| 04/16/2015 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Summary translation of the Cooperation Agreement made by and between Guizhou Taibang and Xinjiang Deyuan",
"Summary translation of the Supplemental Agreement made by and between Guizhou Taibang and Xinjiang Deyuan",
"China Biologic Receives Approval to Purchase Raw Materials BEIJING, China – April 16, 2015 – China Biologic Products, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its subsidiary, Guizhou Taibang Biological Products Co., Ltd. , has received a one-time special approval from the China Food and Drug Administration to purchase up to approximately 143 tonnes of source plasma and plasma pastes from Xinjiang Deyuan Bioengineering Co., Ltd. for a total consideration of up to approximately RMB139 million pursuant to certain agreements entered into between Guizhou Taibang and Xinjiang Deyuan. Source plasma and plasma pastes are raw materials for producing human albumin and intravenous immunoglobulin products. These raw materials are expected ..." |
|
| 03/04/2015 |
8-K
| Quarterly results, Resignation/termination of a director, Appointed a new director |
|
|
|